Isoproterenol inhibits Il-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages

Brain Research Bulletin
G HaskóE S Vizi

Abstract

In a previous study we have demonstrated in conscious endotoxemic mice that isoproterenol, a nonselective agonist of beta-adrenergic receptors, decreased the production of proinflammatory mediators tumor necrosis factor-alpha (TNF-alpha) and nitric oxide (NO), and enhanced the formation of the anti-inflammatory cytokine interleukin-10 (IL-10). In the present study we investigated the effect of isoproterenol on the bacterial lipopolysaccharide (endotoxin, LPS; 10 microg/ml)-induced inflammatory response in RAW 264.7 macrophages in vitro. Pretreatment of cells with isoproterenol (10-300 microM) resulted in an inhibition of TNF-alpha, NO (reflected as its stable breakdown product nitrite), as well as IL-10 production that was paralleled with a restoration of the LPS-induced suppression of mitochondrial respiration. In addition, isoproterenol elevated cAMP accumulation in these cells. Finally, isoproterenol (300 microM) did not influence the nuclear translocation of nuclear factor kappaB. These data demonstrate that isoproterenol potently downregulates the LPS-induced inflammatory response and further support the notion that stimulation of beta-adrenoreceptors can be an effective strategy in the treatment of inflammatory diseases.

References

Jan 1, 1991·Journal of Neuroimmunology·X X HuC F Brosnan
Jan 1, 1987·Journal of Neuroscience Research·K D AckermanD L Felten
Aug 1, 1995·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·T A Tran-ThiP A Baeuerle
Apr 1, 1993·Immunobiology·J M MüllerP A Baeuerle
Nov 1, 1996·European Journal of Immunology·S SubervilleL Baud

❮ Previous
Next ❯

Citations

Feb 11, 2003·Journal of Neuroimmunology·Scott W BrownKrista Fischer-Stenger
Feb 22, 2000·The Veterinary Quarterly·C A IzeboudA S van Miert
Feb 24, 2001·Antioxidants & Redox Signaling·A Okado-MatsumotoN Taniguchi
Sep 9, 2009·Journal of Medicinal Food·Bong Hyun KimIl-Moo Chang
Sep 9, 2010·Cancer Research·Erica K SloanSteven W Cole
Nov 11, 1999·American Journal of Respiratory and Critical Care Medicine·H ZhangA S Slutsky
Mar 11, 1999·Journal of Receptor and Signal Transduction Research·C A IzeboudR F Witkamp
Apr 5, 2005·Immunobiology·Robson Coutinho-SilvaGeoffrey Burnstock
Oct 21, 2009·International Immunopharmacology·V Kumar, A Sharma
Jul 21, 2007·Neurochemistry International·Zsolt SelmeczyGyörgy Haskó
Feb 16, 2005·Journal of Neuroimmunology·Kristie L EnglerKrista Fischer-Stenger
Feb 16, 2005·Biochemical Pharmacology·Dalya Abdulla, Kenneth W Renton
May 26, 2006·Journal of Dental Research·S R Haug, K J Heyeraas
Dec 12, 2018·The Journal of Immunology : Official Journal of the American Association of Immunologists·Hong-Mei LiDong-Keun Song
Jul 14, 2012·Journal of Toxicology and Environmental Health. Part a·Alice A RamosCristina Pereira-Wilson
Sep 25, 2002·Journal of Neuroscience Research·Kenji F TanakaMakoto Sawada
Feb 2, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Aideen Byrne, Denis J Reen
Jul 29, 2005·Pathology, Research and Practice·Dimitrios J KondomerkosPanagiotis Kanavaros

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.